ArticleMolecular biology reports2026
PPP2R3A-RGS19 interaction links Wnt/β-catenin signaling to pathological cardiomyocyte apoptosis in heart failure.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPPP2R3A is a key regulatory subunit of the PP2A B’’ family that encodes PR130 and PR72, two isoforms highly expressed in the heart. It has been implicated in heart failure and represents a potential molecular hub connecting pathological remodeling to disease progression. However, its functional dynamics in pressure overload-induced heart failure remain unclear. This study aims to investigate the expression changes and regulatory mechanisms of PPP2R3A in pressure overload-induced decompensated heart failure.
methodsA chronic pressure overload model was established in C57BL/6J mice using transverse aortic constriction (TAC), and cardiac function and remodeling were assessed by echocardiography and histological analyses. In vitro, PPP2R3A was silenced or overexpressed in H9c2 cardiomyocytes to evaluate its effects on transcription, viability, and apoptosis. Protein interactions and downstream signaling were examined using co-immunoprecipitation, GST pull-down, and Western blotting.
resultsPPP2R3A expression was markedly downregulated in the TAC model, accompanied by impaired systolic function, pathological hypertrophy, and fibrosis. In cardiomyocytes, PPP2R3A knockdown exacerbated apoptosis and reduced viability, whereas overexpression promoted robust survival. Mechanistically, PPP2R3A stabilized the β-catenin destruction complex, thereby suppressing canonical Wnt/β-catenin signaling and preventing maladaptive β-catenin-driven transcription. Proteomic assays identified a direct interaction between PPP2R3A and RGS19, with PPP2R3A negatively regulating RGS19 protein abundance and Ser/Thr phosphorylation.
conclusionsPPP2R3A protects the heart against pressure overload-induced heart failure by stabilizing the β-catenin degradation complex and limiting maladaptive Wnt/β-catenin signaling. Its regulation of RGS19 reveals a novel axis in the transition from compensated to decompensated heart failure, highlighting PPP2R3A as a potential therapeutic target.
Indexed as
Identifiers
42018096What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.